Analysis of multipotent mesenchymal stromal cells used for acute graft‐versus‐host disease prophylaxis

Abstract

A universal single indicator for the prediction of MSC eligibility for aGvHD prophylaxis was not identified. A multiparameter mathematical model for selecting MSC samples effective for the prevention of aGvHD was proposed.

The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review

“…As expected, the bone marrow was chosen as the source of hMSCs in the majority of the articles analyzed. A total of 69 out of the 132 articles selected isolated hMSCs from the bone marrow ( 35 , 37 , 42 – 45 , 47 , 49 – 58 , 60 , 62 – 64 , 66 – 73 , 77 , 79 , 80 , 92 , 95 , 98 , 99 , 102 , 107 , 108 , 110 , 111 , 115 – 118 , 122 , 123 , 125 – 128 , 131 , 132 , 133 , 134 , 135 , 137 , 138 , 143 , 146 , 148 – 150 , 154 – 158 , 161 ). In addition, other common sources of hMSCs included the umbilical cord blood or stroma [29 articles ( 36 , 38 , 39 , 41 , 46 , 61 , 65 , 75 , 76 , 78 , 82 , 85 , 89 , 91 , 93 , 95 , 97 , 100 , 101 , 103 , 107 , 113 , ...…”

“…On the other hand, chronic GvHD can affect any organ ( 168 ). Clinical effects commonly observed after the administration of hMSCs included an increase in the survival rates ( 35 , 36 , 39 – 41 , 44 , 45 , 48 , 49 , 51 , 56 – 62 , 65 – 68 , 71 , 72 ), a decrease in the severity of the symptoms of the disease ( 33 – 36 , 38 – 46 , 52 – 59 , 61 – 64 , 66 – 68 , 71 ) and a reduction in the incidence of acute and chronic GvHD ( 51 , 53 , 54 , 65 ) in patients submitted to hematopoietic stem cell transplantation. Among the studies conducted in mice, the cumulative survival rate, the clinical score of the disease and the rate of change in body weight were the outcomes used by most animal studies selected in this systematic review to assess the potential of hMSCs administration for the treatment of GvHD.…”

The ability of multipotent mesenchymal stromal cells from the bone marrow of patients with leukemia to maintain normal hematopoietic progenitor cells

“…Total cell production of MSCs from patients with CML did not differ from the donors, whereas production of MSCs from patients with ALL and AML decreased at the moment of diagnosis. It is known that total MSCs production decreases with age . The median age of CML patients was higher than donors, but total MSCs production did not differ significantly.…”

Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells

“…From the harvested bone marrow, MSCs were isolated and cultured according to the standard protocol described above, with the addition of 10% fetal calf serum (FCS) (Hyclone, Thermo Scientific, South Logan, USA) instead of plasma enriched with platelets. From these bone marrow samples, CFU-Fs were analyzed according to a standard protocol [ 9 ].…”

“…MSCs have been used since 2000 to treat various hematologic and autoimmune diseases, including acute graft versus host disease (aGvHD). Since 2008, in the National Research Center for Hematology, the study on the use of MSCs for aGvHD prevention has been conducted [ 7 – 9 ]. Since that time, for each patient, MSCs from bone marrow donors have been individually cultured.…”